Co-development and Out Licensing
To provide excellent drugs to patients and medical service providers as early as possible, we promote cooperative development and sales and out-licensing of our compounds through alliances based on the targeted disease or compound if it is more effective to let a partner with required know-how handle the matter or to conduct joint development.
| Licensee | Product Name or Development Code | Drug Class | Indication(s) | Territory | Time |
| Tobira |
TAK-220/TAK-652 |
CCR5 antagonist |
HIV Infection |
Worldwide |
Aug.07 |
| Peninsula Pharmaceuticals |
TAK-599 |
Cephalosporin |
Infection |
Worldwide except Japan |
Sep.03 |